Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Outpatient Intensive Induction Chemotherapy for Acute Myeloid Leukemia and Advanced Myelodysplastic Syndrome

Frances Linzee Mabrey, MD, Kelda M Gardner, PA-C, Kathleen Shannon Dorcy, RN, PhD, Andrea Perdue, PA-C, Heather Smith, PA-C, Alicyn Marie Davis, ARNP, Cody Hammer, Donelle Rizzuto, RN, Sunny So, RN, Anna Rosen, Kim Quach, Bart L. Scott, MD, Paul C. Hendrie, MD PhD, Mary Beth M. Percival, MD, Roland B. Walter, MD PhD MS, Frederick R. Appelbaum, MD, Elihu H. Estey, MD, Pamela S. Becker, MD PhD

Blood (2017) 130 (Supplement 1): 3851.

https://doi.org/10.1182/blood.V130.Suppl_1.3851.3851

Published: 2017

Journal Articles

Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Mazyar Shadman, MD MPH, Raya Mawad, MD, Carol Dean, MPH, BSN, Kathleen Shannon-Dorcy, RN,PhD, Vicky Sandhu, MD MPH, Paul C. Hendrie, MD PhD, Bart L. Scott, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, John Pagel, MD PhD, Elihu H. Estey, MD

Blood (2014) 124 (21): 3732.

https://doi.org/10.1182/blood.V124.21.3732.3732

Published: 2014

Journal Articles

Using Natural Language Processing to Determine Chemotherapeutic Regimens Administered within 30 Days Prior to Death in Acute Myelogenous Leukemia Patients

Hanahlyn M Park, BSN, MN(c), Vicky Sandhu, MD MPH, Paul Fearn, MBA, PhDc), Kathleen Shannon Dorcy, RN, MN, PhD, Elihu H. Estey, MD, Emily Silgard, MS

Blood (2014) 124 (21): 1267.

https://doi.org/10.1182/blood.V124.21.1267.1267

Published: 2014

Journal Articles

Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Platelet and Neutrophil Recovery.

Laura F Newell, MD, Hu Xie, John M. Pagel, MD, PhD, Ravinder K Sandhu, MD, Pamela S Becker, MD, PhD, Roland B. Walter, MD, PhD, Kathleen Shannon Dorcy, RN, MN, Ph.C, Janis L Abkowitz, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2012) 120 (21): 2598.

https://doi.org/10.1182/blood.V120.21.2598.2598

Published: 2012

Journal Articles

NCI Common Toxicity Criteria and Mortality After Chemotherapy for Acute Myeloid Leukemia (AML)

Joshua R. Veatch, MD, PhD, Ravinder K Sandhu, MD, Kathleen Shannon-Dorcy, RN, John M. Pagel, MD, PhD, Pamela S. Becker, MD, PhD, Stephen Petersdorf, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2012) 120 (21): 1479.

https://doi.org/10.1182/blood.V120.21.1479.1479

Published: 2012

Journal Articles

Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study.

Mazyar Shadman, MD, MPH, Jack M. Lionberger, MD, PhD, Raya Mawad, MD, Ravinder K Sandhu, MD, Carol Dean, RN, Kathleen Shannon-Dorcy, RN, Kyle Wathen, PhD, Bart L Scott, MD, MS, Roland B. Walter, MD, PhD, Pamela S. Becker, MD, PhD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD, John M. Pagel, MD, PhD

Blood (2012) 120 (21): 2622.

https://doi.org/10.1182/blood.V120.21.2622.2622

Published: 2012

Journal Articles

Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Speed of Neutrophil and Platelet Recovery

Laura F Newell, MD, Ravinder K Sandhu, Pamela S Becker, MD, PhD, John M. Pagel, MD, PhD, Paul C. Hendrie, MD, PhD, Roland B. Walter, MD, PhD, Stephen H. Petersdorf, MD, Kathleen Shannon Dorcy, RN, MN, Ph.C, Janis L. Abkowitz, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2011) 118 (21): 1498.

https://doi.org/10.1182/blood.V118.21.1498.1498

Published: 2011

Journal Articles

Innovative Phase I/II Statistical Design in Combination Chemotherapy That Combines Toxicity and Efficacy Parameters to Increase Study Efficiency: Bendamustine and Idarubicin in De Novo Adult AML

Jack M. Lionberger, MD, PhD, Kathleen Shannon Dorcy, RN, MN, Ph.C, Carol Dean, RN, Nathan Holm, BS, Bart Lee Scott, MD, J. Kyle Wathen, PhD, Elihu H. Estey, MD, John M. Pagel, MD, PhD

Blood (2011) 118 (21): 1552.

https://doi.org/10.1182/blood.V118.21.1552.1552

Published: 2011

Journal Articles

Evaluation of Early Discharge After Hospital Treatment of Neutropenic Fever In Acute Myelogenous Leukemia (AML).

Victor A. Chow, Kathleen Shannon Dorcy, RN, MN, Ph.C, Stephen H. Petersdorf, MD, Kelda M. Gardner, PA-C, Pamela S. Becker, MD, PhD, Roland B. Walter, MD, PhD, John M. Pagel, MD, PhD, Paul C. Hendrie, MD, PhD, Andrei R. Shustov, MD, Janis L. Abkowitz, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2010) 116 (21): 3806.

https://doi.org/10.1182/blood.V116.21.3806.3806

Published: 2010

NARROW

Outpatient Intensive Induction Chemotherapy for Acute Myeloid Leukemia and Advanced Myelodysplastic Syndrome

Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Using Natural Language Processing to Determine Chemotherapeutic Regimens Administered within 30 Days Prior to Death in Acute Myelogenous Leukemia Patients

Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Platelet and Neutrophil Recovery.

NCI Common Toxicity Criteria and Mortality After Chemotherapy for Acute Myeloid Leukemia (AML)

Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study.

Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Speed of Neutrophil and Platelet Recovery

Innovative Phase I/II Statistical Design in Combination Chemotherapy That Combines Toxicity and Efficacy Parameters to Increase Study Efficiency: Bendamustine and Idarubicin in De Novo Adult AML

Evaluation of Early Discharge After Hospital Treatment of Neutropenic Fever In Acute Myelogenous Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only